Unlock instant, AI-driven research and patent intelligence for your innovation.

Classification and actionability indices for lung cancer

A feasible, lung cancer technology, applied to AKT1, IK3CA, BRAF and HRAS genes, can solve the problem of unavailable genetic variation

Active Publication Date: 2015-11-25
LIFE TECH CORP
View PDF24 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the variety of genetic variants currently available requires far more tissue than can be obtained from a typical tumor biopsy or resection
In addition, tests are not available for many genetic variants, and there are no tools that can recommend treatment based on a comprehensive scan of the many known actionable genetic variants

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Classification and actionability indices for lung cancer
  • Classification and actionability indices for lung cancer
  • Classification and actionability indices for lung cancer

Examples

Experimental program
Comparison scheme
Effect test

example I

[0144] Genomics and genetic variant data from ONCOMINE of Life Technologies and Compendia Biosciences TM Concepts Edition and ONCOMINE TM Acquired from PowerTools, a suite of web applications and web browsers that integrate and unify high-throughput cancer profiling data through systematic collection, management, ontology, and analysis. In addition, mutant gene variant data was also obtained from the management and analysis of life technologies and general biosciences of next generation sequencing data available from The Cancer Genome Atlas (TCGA) portal.

[0145] Data obtained from TCGA contain mutational results from datasets processed and annotated by different genome sequencing centers. All mutational data characterized in TCGA are somatic mutational data containing mutational variants specific to tumor samples and not observed in normal tissue samples obtained from the same individual. To obtain consistent variant annotations, mutations obtained from TCGA were re-annota...

example II

[0156] A panel of 177 patients with squamous cell carcinoma of the lung was characterized by next generation sequencing methods, and according to the method of Example 1, the genetic variants were mapped onto this population. The prevalence of gene variants in the AI1, AI2, and AI3 categories in the TCGA squamous cell carcinoma 177 patient cohort are shown in Tables 9-10.

[0157] Other genes are presented in Tables 11-14 with their evidence levels and corresponding feasibility.

example III

[0159]The patient presented with advanced NSCLC. Testing was performed in a cohort to determine the mutation status of the highly available NSCLC biomarkers in Table 11 to retain limited tumor biopsy samples. A report is generated summarizing the mutation status of the sample and the corresponding viability index. Based on the mutation status of the patient's tumor, the course of treatment is determined.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with lung cancer. The compositions, kits, and methods include a set of oligonucleotides, typically primers and / or probes that can hybridize to identify a gene variant. The methods disclosed herein provide for a mutation status of a tumor to be determined and subsequently associated with an actionable treatment recommendation.

Description

Background technique [0001] Lung cancer is the leading cause of cancer death in both men and women. It is a fast-growing and highly fatal disease. Nearly 60% of people diagnosed with lung cancer die within one year of diagnosis, and about 75% die within 2 years. There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). About 85% of lung cancers are NSCLC. There are 3 subtypes of NSCLC that differ in size, shape, and biochemical composition. About 25-30% of all lung cancers are squamous cell carcinomas. Adenocarcinomas (eg, bronchioloalveolar carcinoma) account for about 40% of lung cancers and are usually found in the outer regions of the lung. Large cell undifferentiated carcinoma accounts for about 10-15% of all lung cancers. [0002] SCLC and NSCLC are treated in very different ways. SCLC is primarily treated with chemotherapy alone or in combination with radiation. Compared with the treatment used for SCLC, surge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/106C12Q2600/156A61P11/00A61P35/00A61P43/00
Inventor S·班德拉D·罗斯S·萨迪斯P·韦恩加德
Owner LIFE TECH CORP